186463-41-2

Basic information

• Product Name: Carbamic acid, [(1S)-3-chloro-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester
• CAS NO: 186463-41-2
• Molecular Formula: C18H20ClNO3
• Molecular Weight: 333.815
• Mol File: 186463-41-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1S)-3-chloro-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-3-chloro-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester(186463-41-2)
• EPA Substance Registry System: Carbamic acid, [(1S)-3-chloro-2-hydroxy-1-(phenylmethyl)propyl]-, phenylmethyl ester(186463-41-2)

Safety Data

• Hazardous Substances Data: 186463-41-2(Hazardous Substances Data)

Upstream product

• 1161-13-3 N-Cbz-L-Phe 
• 26049-94-5 (S)-benzyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate 

Downstream Products

• 150767-05-8 (S)-2-(phenylmethoxycarbonyl)amino-1-phenylbut-3-ene 
• 137515-66-3 2(R)-3(S)-1,2-epoxy-3-phenylmethoxycarbonylamino-4-phenylbutane 
• 198020-19-8 (2R,2S)-(3S)-1,2-epoxy-3-phenylmethoxycarbonylamino-4-phenylbutane 
• 128018-44-0 N-benzyloxycarbonyl-3(S)-amino-1,2(S)epoxy-4-phenylbutane 

Relevant articles and documents

Rh(iii)-Catalyzed diastereoselective transfer hydrogenation: An efficient entry to key intermediates of HIV protease inhibitors

A highly efficient diastereoselective transfer hydrogenation of α-aminoalkyl α′-chloromethyl ketones catalyzed by a tethered rhodium complex was developed and successfully utilized in the synthesis of the key intermediates of HIV protease inhibitors. With the current Rh(iii) catalyst system, a series of chiral 3-amino-1-chloro-2-hydroxy-4-phenylbutanes were produced in excellent yields and diastereoselectivities (up to 99% yield, up to 99?:?1 dr). Both diastereomers of the desired products could be efficiently accessed by using the two enantiomers of the Rh(iii) catalyst.

Antiviral drug and its pharmaceutical composition

The invention relates to an antiviral medicine and a medicine composition thereof, in particular relates to an anti-human immunodeficiency virus (HIV) medicine and a medicine composition thereof, and especially relates to a medicine which can be taken as

Process for producing 3-amino-2-oxo-1-halogenopropane derivatives

Compounds formed by reacting a protected amino acid with an alkali metal enolate of an alkyl acetate are reacted with a halogenating agent for halogenation of the 2-position, or a protected amino acid is reacted with an alkali metal enolate of an alkyl halogenoacetate, to form a 4-amino-3-oxo-2-halogenobutanoic acid ester derivative, and hydrolysis and decarboxylation are conducted to produce a 3-amino-2-oxo-1-halogenopropane derivative or its salt. The present method is a useful process for producing a 3-amino-2-oxo-1-halogenopropane derivatives which can easily be converted to a 3-amino-1,2-epoxypropane.